|
Toggle Summary
May 15, 2017
|
Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA
|
Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA
|
|
Toggle Summary
May 4, 2017
|
Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates
|
Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates
|
|
Toggle Summary
April 27, 2017
|
Minerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017
Management to host conference call
|
Minerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017
|
|
Toggle Summary
March 21, 2017
|
Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors
|
Minerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors
|
|
Toggle Summary
March 13, 2017
|
Minerva Neurosciences Reports Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates
|
Minerva Neurosciences Reports Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates
|
|
Toggle Summary
March 6, 2017
|
Minerva Neurosciences to Report Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates on March 13, 2017
|
Minerva Neurosciences to Report Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates on March 13, 2017
|
|
Toggle Summary
February 28, 2017
|
Minerva Neurosciences to Present at Cowen and Company 37th Annual Health Care Conference on March 7, 2017
|
Minerva Neurosciences to Present at Cowen and Company 37th Annual Health Care Conference on March 7, 2017
|
|
Toggle Summary
February 21, 2017
|
Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia
|
Minerva Neurosciences to Host R&D Day Focused on Unmet Needs and Emerging Treatment Strategies in Schizophrenia
|
|
Toggle Summary
January 20, 2017
|
Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function
|
Additional Data Analyses From Phase IIb Trial of MIN-101 in Schizophrenia Underscore Benefit in Multiple Measurements of Cognitive Function
|
|
Toggle Summary
December 20, 2016
|
Minerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer
|
Minerva Neurosciences Names Michael Davidson, M.D. as Chief Medical Officer
|
